



PeptiDream Announces Milestone from Second Program of Macrocyclic Peptide Drug Discovery Alliance with Santen Pharmaceutical

KANAGAWA, JAPAN – May 12th, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) announced today that it has achieved a milestone in its discovery alliance with Osaka-based Santen Pharmaceutical Co., Ltd., (“Santen”), for the identification of candidates meeting pre-defined criteria, in the second discovery program between the companies. This achievement entitles PeptiDream to receive an undisclosed payment per the research collaboration and drug discovery and development agreement between PeptiDream and Santen announced September 25, 2018.

Under the terms of the agreement, PeptiDream uses its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications. In addition to the current achieved milestone, PeptiDream is also eligible for future pre-clinical and clinical development milestones, as well as royalties on future sales, as this discovery and development program continues to advance.

[Comment from Keiichi Masuya, PhD., EVP of PeptiDream]

“We are delighted with the achievement of the first development milestone for the second program in our Santen collaboration, which was made in a remarkably short period of time and now allows us to proceed to optimization and pre-clinical studies. We look forward to continuing the advancement of this second program, as well as the first program which continues to make extraordinary progress, toward clinical studies, along with our ultimate goal of contributing to the development of next-generation drugs in the area of ophthalmic diseases.”

<About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-

of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.

Enquiries:

PeptiDream Inc.

Mie Yamazaki IR - (Kanagawa)

EMAIL: m-yamazaki@peptidream.com